SERPIVITE Drug Patent Profile
✉ Email this page to a colleague
When do Serpivite patents expire, and when can generic versions of Serpivite launch?
Serpivite is a drug marketed by Vitarine and is included in one NDA.
The generic ingredient in SERPIVITE is reserpine. There are nineteen drug master file entries for this compound. Additional details are available on the reserpine profile page.
Summary for SERPIVITE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 101 |
Patent Applications: | 2,006 |
Formulation / Manufacturing: | see details |
DailyMed Link: | SERPIVITE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for SERPIVITE
US Patents and Regulatory Information for SERPIVITE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vitarine | SERPIVITE | reserpine | TABLET;ORAL | 009645-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |